Navigation Links
SCOLR Pharma, Inc. Announces Initial Closing of Private Placement
Date:6/16/2011

are convertible.  The exercise price of such warrant is $0.0625 per share.

The Debentures were offered in the private placement pursuant to Regulation D under the Securities Act of 1933, as amended (the "Securities Act").  Neither the Debentures, nor the underlying common stock into which the Debentures are convertible, have been registered under the Securities Act, and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from registration requirements. This press release does not and will not constitute an offer to sell or the solicitation of an offer to buy Debentures or any other security of the Company, and is being issued pursuant to the safe-harbor provisions of Rule 135c under the Securities Act.

FORWARD-LOOKING STATEMENTS — The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements (statements other than statements of historical fact).  Forward-looking statements may generally be identified by the inclusion of the words "may," "will," "would," "could," "believes," "expects," "anticipates," "intends," "plans," "projects," "considers" and similar expressions).  This news release contains forward-looking statements, including information regarding a private securities offering conducted by SCOLR Pharma, Inc., and the use of proceeds therefrom. These forward-looking statements are based on certain assumptions and expectations of SCOLR Pharma, Inc., and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks and uncertainties referenced from time to time in SCOLR Pharma, Inc.'s filings with the Securities and Exchange Commission.  Readers are cautioned not to place undue reliance on such forward-looking
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
2. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
3. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
4. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
6. Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
7. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
8. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
9. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
10. Sinobiopharma, Inc. Appoints New Director of Marketing
11. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Terracon Corporation has announced the introduction ... . This addition to the company’s industry-leading line ... polyethylene and available in 125 or 250 gallon capacities. ... two weeks or less. , The new pre-engineered TerraPure ... Terracon’s existing TerraPure tank line – plus quick turnaround. ...
(Date:9/17/2014)... , Sept. 17, 2014 Hussey ... of MD-Cu 29 antimicrobial copper, announces Gilmour Academy ... to the first EPA-registered antimicrobial solid touch surface to ... is a reasonably priced surface that kills greater than ... hours of exposure. 1 , ...
(Date:9/17/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: ... proprietary technologies and products for advanced microarray diagnostics, today ... trading in the United States ... commence on September 17, 2014 on the OTCQX under ... on the TSX Venture Exchange under its existing symbol ...
(Date:9/17/2014)... MARLBOROUGH, Mass. , Sept. 17, 2014 /PRNewswire/ ... ), a biotechnology company focused on discovering, developing ... needs using RNA-targeted technologies, today announced that it has ... Patent and Trademark Office on its unique delivery ... ® ) to phagocytic cells for the treatment ...
Breaking Biology Technology:Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... proxy, FOR the Election of, Two ... May 15 /PRNewswire/ - The Concerned Shareholders of Biovail ... (TSX:BVF) continues to mislead its shareholders by making the ... requisition was simply about governance reform and has already ...
... Nile Therapeutics, Inc. (Nasdaq: NLTX ... therapeutics for heart failure patients, received notification from the ... has released the Company,s CD-NP development program from clinical ... the FDA the finalized protocol for the Company,s planned ...
... Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced ... 15 Proteolix, Inc. today announced that data from ... solid tumors will be presented at the 2009 Annual ... being held May 29 - June 2, 2009 in ...
Cached Biology Technology:The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 2The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 3The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 4The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 5The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 6The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 7Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 2Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA 3Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 2Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 3
(Date:9/18/2014)... several disciplines will be celebrated tonight at the third ... improving the health of premature infants and in paving ... researchers, whose work was supported by the National Science ... Atomic Energy Commission, will be honored at a ceremony ... bipartisan group of Members of Congress will be on ...
(Date:9/18/2014)... world-leading provider of scientific, technical and medical information ... Society (ARMS), recognized the academic research achievements of ... Researcher of the Year Awards. , The award ... Centre and in conjunction with the ARMS 2014 ... and New Zealand,s scientific community. Guest of honour ...
(Date:9/18/2014)... form of camouflage: you don,t just blend in, the ... as uncommon as you might think. Kathryn Feller, from ... the larval life stages of many marine species are ... that most creatures cannot make transparent. Feller explains that ... individual eye unit with an opaque pigment to prevent ...
Breaking Biology News(10 mins):3rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Transparent larvae hide opaque eyes behind reflections 2
... It may be news to its bankers, but Charlotte, the biggest ... financial industry, is actually an old growth forest. At least ... Charlotte is famous for having two kinds of green. It is ... residential neighborhoods and near-suburbs are also known for their lush yards ...
... Health Research Charity --Presents 2007 Prizes ,for Outstanding Psychiatric ... Prize winners have significantly contributed to the ... mental disorders NEW YORK, N.Y., Oct. 16, 2007Five ... be presented to scientists of great achievement by NARSAD, ...
... German . , Mammography continues to be ... breast cancer. However, because this technique is not as ... not deliver reliable results for every level of tissue ... works with rays of near-infrared (NIR) light instead of ...
Cached Biology News:Ecologists discover city is 'uber-forest' for big owls 2Ecologists discover city is 'uber-forest' for big owls 3Ecologists discover city is 'uber-forest' for big owls 4Ecologists discover city is 'uber-forest' for big owls 5Ecologists discover city is 'uber-forest' for big owls 6NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 2NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 3NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 4NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 5Contrast agent trials in swine 2
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
... OA-Hy cis- 9-Octadecenoyl-N-hydroxylamide Oleoyl-N-hydroxylamide ... INERT GAS. A potent inhibitor of MMP-2 ... i = 1.7 μM). Purity: ... or DMSO. Unstable in solution, reconstitute just ...
MAb to Vasopressin Preservative: NaN3...
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
Biology Products: